Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Hepion Pharmaceuticals Inc

HEPA
Current price
0.29 USD -0.0031 USD (-1.07%)
Last closed 0.28 USD
ISIN US4268971045
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 3 182 837 USD
Yield for 12 month -99.58 %
1Y
3Y
5Y
10Y
15Y
HEPA
21.11.2021 - 28.11.2021

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor is in Phase 2b clinical trial to target multiple pathologic pathways involved in the progression of liver disease and treat non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey. Address: 399 Thornall Street, Edison, NJ, United States, 08837

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

30.00 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-67 131 USD

Last Year

-67 131 USD

Current Quarter

Last Quarter

Key Figures HEPA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -19 315 820 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -122.71 %
PEG Ratio
Return On Equity TTM -487.03 %
Wall Street Target Price 30.00 USD
Revenue TTM
Book Value -25.57 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -5 519.77 USD
Diluted Eps TTM -5 519.77 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics HEPA

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History HEPA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor 1:50
Payout Ratio TTM
Last Split Date 18.03.2025

Stock Valuation HEPA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.096
Price Book MRQ 2.11

Financials HEPA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators HEPA

For 52 weeks

0.25 USD 79.50 USD
50 Day MA 3.07 USD
Shares Short Prior Month 7 979 511
200 Day MA 24.32 USD
Short Ratio 0.10
Shares Short 199 814
Short Percent 18.50 %